Vise Technologies Inc. Purchases Shares of 8,469 Globus Medical, Inc. $GMED

Vise Technologies Inc. purchased a new stake in Globus Medical, Inc. (NYSE:GMED) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 8,469 shares of the medical device company’s stock, valued at approximately $739,000.

A number of other large investors have also recently added to or reduced their stakes in the company. William Blair Investment Management LLC lifted its stake in Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after acquiring an additional 414,134 shares during the last quarter. Sculptor Capital LP lifted its stake in Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after acquiring an additional 667,850 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after acquiring an additional 1,908,795 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Globus Medical by 72.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock valued at $115,166,000 after acquiring an additional 842,547 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in Globus Medical by 8.3% in the third quarter. Marshall Wace LLP now owns 1,711,909 shares of the medical device company’s stock valued at $98,041,000 after acquiring an additional 131,433 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 18.38% of the company’s stock.

Wall Street Analysts Forecast Growth

GMED has been the subject of a number of recent analyst reports. Royal Bank Of Canada increased their price target on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Truist Financial set a $115.00 price target on shares of Globus Medical in a research note on Wednesday, February 25th. Piper Sandler reiterated an “overweight” rating on shares of Globus Medical in a research note on Tuesday. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $106.36.

Globus Medical Stock Performance

NYSE GMED opened at $81.02 on Thursday. The firm has a 50-day moving average of $86.03 and a 200-day moving average of $88.19. The stock has a market cap of $11.00 billion, a PE ratio of 18.84, a P/E/G ratio of 1.70 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The company had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.